A PYMNTS Company

Antitrust Chronicle® – Patents, Drugs & Antitrust

Spring 2014, Volume 4, Number 2

Dear Readers, This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to…

Read More